Keryx Biopharmaceuticals, Inc. (KERX.OB) Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
Keryx Biopharmaceuticals, Inc., a developer of medically important pharmaceutical products for the treatment of life-threatening diseases, recently announced that the…